Related Experiment Video
Updated: Dec 23, 2025
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.6K
New perspective in heart failure management: could myosin activators be the answer?
Stefan Andrei1, Corina Iorgoveanu2
1CNHO des Quinze-Vingts, Service de Médecine Interne, Paris, France.
Discoveries (Craiova, Romania)
|April 21, 2020
Summary
Acute heart failure requires novel treatments. Omecamtiv mecarbil, a cardiac myosin activator, offers a new approach to improve heart contractility without the side effects of current drugs, though more research is needed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is a major cause of hospitalization globally.
- Current treatments for acute heart failure, especially in hemodynamically unstable patients, are limited and carry risks.
- There is a need for innovative therapeutic strategies to manage heart failure effectively.
Purpose of the Study:
- To introduce omecamtiv mecarbil as a novel therapeutic agent for heart failure.
- To highlight its unique mechanism of action in improving myocardial contractility.
- To discuss its potential as an alternative to existing inotropic agents.
Main Methods:
- Review of existing studies and clinical data on omecamtiv mecarbil.
- Analysis of its mechanism as a cardiac myosin activator.
- Comparison with current inotropic therapies for heart failure.
Main Results:
- Omecamtiv mecarbil selectively increases cardiac contractility.
- It operates via a novel mechanism, distinct from traditional inotropic agents.
- Preliminary studies suggest promising efficacy and a potentially favorable safety profile.
Conclusions:
- Omecamtiv mecarbil represents a promising new therapeutic avenue for acute heart failure.
- Its innovative mechanism may overcome limitations of current treatments.
- Further clinical validation is essential to confirm its role in heart failure management.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
811
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
811
01:30Heart Failure V: Medical Management
159
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
159
01:29Cardiomyopathy V: Interprofessional Care
228
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
228
01:22Heart Failure VI: Adjunct Therapies
184
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
184
01:22Heart Failure Drugs: β-Blockers
675
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
675